In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Aimmune Therapeutics, Inc.. Trade Record

NASDAQ:AIMT Aimmune Therapeutics, Inc. stock gains 5.30% Exit Feb 13, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart AIMT Jan 30, 2019, priceSeries
About Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.

Trade Information
Trade Type
Entry Date
Jan 30, 2019
Entry Price
Sell Date
Feb 13, 2019
Sell Price
Net Gain
Hold Time
10 Trading Days